Product
Luvadaxistat
Aliases
NBI-1065844, TAK-831
3 clinical trials
1 indication
Indication
SchizophreniaClinical trial
A Phase 2, 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Dose Levels of TAK-831 in Adjunctive Treatment of Adult Subjects With Negative Symptoms of SchizophreniaStatus: Completed, Estimated PCD: 2020-12-29
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Subjects With Cognitive Impairment Associated With Schizophrenia, Followed by Open-Label TreatmentStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate Pharmacodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of TAK-831 in Adult Subjects With SchizophreniaStatus: Completed, Estimated PCD: 2020-12-21